Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease
NCT02194985
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
84
Enrollment
INDUSTRY
Sponsor class
Conditions
Fabry Disease
Interventions
DRUG:
migalastat HCl 150 mg
Sponsor
Amicus Therapeutics